Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

This trial will evaluate the feasibility, toxicity, and efficacy of docetaxel/estramustine, as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local therapy.

Key facts

Study ID
NCT00193271
Run by
SCRI Development Innovations, LLC
People needed
30
Starts
2004-08-01
Expected to finish
2007-05-01
Last updated by the study team
2011-05-03

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.